In a significant milestone for Bern-based LEM Surgical, the pioneering surgical robotics company proudly announced the successful closure of its Series B funding round, amassing a noteworthy €23.6 million. This achievement marks an impactful leap forward for the company and stands as a testament to investors’ unwavering confidence in its groundbreaking approach to surgical technology.
The resounding success of this funding round owes much to the enthusiastic participation of new investors from both the United States and Switzerland. This substantial financial infusion positions LEM Surgical strategically, accelerating its product development endeavors. The company has set its sights on achieving readiness for FDA submission by the latter half of 2024, leveraging this capital to make significant strides in the realm of surgical robotics.
Yossi Bar, the visionary founder and CEO of LEM Surgical, expressed the company’s bold mission: “Our vision is to revolutionize surgical procedures, enhancing the experiences of surgeons, clinical teams, and hospitals involved in robotic surgery. The trust and support from our new investors underscore their unwavering belief in the future success of our pioneering technology.”
At the forefront of innovation, LEM Surgical is dedicated to crafting the next generation of robotic surgery platforms. Their primary focus lies in surpassing the capabilities of existing robotic systems, particularly in the specialized domain of spine surgery.
Founded in 2021 by a team comprising Prof. Dr. Stefan Weber (CEO, CAScination AG), Marco Matulic (CTO, CAScination AG), Simon Michel (CEO, Ypsomed Group), Prof. Dr. Andreas Raabe (Director, Department of Neurosurgery, Inselspital Bern), and Yossi Bar (previously Director R&D at Mazor Robotics Ltd), LEM Surgical stands as a collaborative endeavor of seasoned professionals committed to pushing the boundaries of surgical innovation.
This remarkable achievement not only signifies a financial milestone but also underscores the company’s unwavering commitment to driving the evolution of surgical robotics. With an injection of substantial capital, LEM Surgical is poised to elevate its technological prowess, aiming to redefine the landscape of surgical procedures.
The company’s strategic direction, guided by a team of experts from diverse backgrounds, instills confidence in its ability to pioneer advancements in surgical robotics. This investment not only propels LEM Surgical’s trajectory forward but also underscores the burgeoning confidence in the future of robotic-assisted surgery.
As LEM Surgical prepares to navigate the regulatory landscape and gear up for FDA submission in the latter part of 2024, the infusion of capital at this pivotal juncture fortifies its position as an industry trailblazer. The company’s commitment to enhancing surgical outcomes through innovative technology heralds a promising future for the field of robotic surgery.
